Toward a more efficient therapy for a specific form of leukemia
Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius Research Centre, K.U. Leuven, under the direction of Peter Carmeliet, have investigated the role of placental growth factor (PlGF) in mice with CML. Blocking this growth factor increases the life expectancy of these mice, even in those resistant to imatinib.
In our body, white blood cells combat foreign intruders, such as viruses and bacteria. In chronic myeloid leukemia, the formation of granulocytes, a particular type of white blood cells, is disturbed. The cells in the bone marrow which should grow into white blood cells show an uncontrolled increase in numbers as a result of a disruption in the maturing process. This uncontrolled growth may damage various tissues and adversely affect the production of normal blood cells in the bone marrow. A shortage of white blood cells makes patients more susceptible to infection.
Under normal circumstances, our body very accurately regulates the production of white blood cells. This process is triggered by targeted activation of tyrosine kinase. In most forms of CML, a deviant chromosome is present - the Philadelphia chromosome - which gives rise to BCR-ABL1 fusion kinase. This kinase causes the trouble, leading to the increase in CML cells. Existing medicines (imatinib) therefore target this kinase.
While the effect of imatinib in CML patients is usually quite favorable, the use of imatinib is often not sufficient to remove the diseased cells from the body. Sometimes the disease is already too advanced at the start of treatment, or there is resistance.
Researchers from the team headed by Peter Carmeliet have studied the role of placental growth factor (PlGF) in leukemia and the therapeutic potential of PIGF inhibitors. Recent research conducted by Peter Carmeliet had already shown that antibodies against PlGF (antiPlGF) can inhibit the growth of particular tumors.
The present study proves that PlGF also plays a role in CML. The researchers have recorded increased PIGF values in both mice and humans. It appears that PIGF does not only stimulate the division of CML cells but also encourages the formation of blood vessels in bone marrow. Finally, inhibiting PlGF in mice with CML leads to higher life expectancy, even in those mice that are resistant to the current medicine imatinib. All of these findings indicate that the therapeutic potential of PIGF inhibitors in CML needs to be investigated further.
Provided by Flanders Institute for Biotechnology
- A potential new way to make a good anti-leukemia drug even better Oct 20, 2008 | not rated yet | 0
- Therapeutic effect of imatinib improved with addition of chloroquine Apr 13, 2009 | not rated yet | 0
- Genetics of imatinib resistance in acute lymphoblastic leukemia Aug 30, 2007 | not rated yet | 0
- Activation of LYN kinase is associated with imatinib-resistance in CML patients Jun 25, 2008 | not rated yet | 0
- Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy May 29, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
5 hours ago Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
Aggressive forms of bladder cancer involve the protein PODXL – a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.
Cancer 47 minutes ago | 5 / 5 (1) | 0
For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized ...
Cancer 1 hour ago | 5 / 5 (1) | 0 |
More than half of patients diagnosed with Non-Hodgkin Lymphoma (NHL) are now surviving the disease thanks to improved diagnosis and treatment, according to a new report1 from Cancer Research UK.
Cancer 1 hour ago | 5 / 5 (1) | 0
(Medical Xpress)—Researchers at the University of Virginia School of Medicine have identified a promising target for treating glioblastoma, one that appears to avoid many of the obstacles that typically frustrate efforts ...
Cancer 2 hours ago | 3.5 / 5 (2) | 0 |
(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.
Cancer 16 hours ago | not rated yet | 0
(Medical Xpress)—Scientists from the Joint Center for Structural Genomics (JCSG) at SLAC National Accelerator Laboratory have determined the 3-D structure of the chemically active part of an enzyme involved ...
57 minutes ago | not rated yet | 0 |
(Medical Xpress)—Research by U of T Mississauga psychology professor Glenn Schellenberg reveals that two key personality traits – openness-to-experience and conscientiousness—predict better than IQ ...
37 minutes ago | not rated yet | 0 |
Professor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, was part of an international team that discovered the previously unknown pathway of how the bacterium colonizes people.
15 minutes ago | 5 / 5 (1) | 0 |
Scientists at Newcastle University have shed new light on how the brain tunes in to relevant information.
12 minutes ago | not rated yet | 0 |
Parents naturally are concerned for their children's safety, particularly when there is news of a child abduction that happens close to home. Finding the balance between emotions and the "teachable moment" as parents talk ...
1 hour ago | not rated yet | 0
New techniques in imaging of brain activity developed by Jean Gotman, from McGill University's Montreal Neurological Institute, and his colleagues lead to improved treatment of patients suffering from epilepsy. The combination ...
12 minutes ago | not rated yet | 0